The availability of Micro-Neighborhood® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing OptimizeRx presents panel session at Digital Pharma East: Unlocking Opportunity through HCP+DTC Alignment in Omnichannel Oncology Marketing WALTHAM, Ma., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences ...

OptimizeRx Corp. (OPRX) has been beaten down lately with too much selling pressure. While the stock has lost 12.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 OPRX Nasdaq Capital Market FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Numb ...

Financial Data and Key Metrics Changes - The company reported Q2 2024 revenue of $18.8 million, a 36% increase from $13.8 million in Q2 2023 [11] - Gross margin improved from 56.6% in Q2 2023 to 62.2% in Q2 2024, attributed to higher DAAP-related revenue and a favorable channel partner mix [11] - The net loss for Q2 2024 was $4 million, or $0.22 per share, compared to a net loss of $4.1 million, or $0.24 per share, in Q2 2023 [11] - Non-GAAP net income for Q2 2024 was $0.3 million, or $0.02 per share, compared to a non-GAAP net loss of $0.2 million, or $0.01 per share, in the same period last year [12] - Adjusted EBITDA for Q2 2024 was a gain of $0.5 million, compared to a loss of $0.8 million in Q2 2023 [12] - Operating cash flow for the first half of 2024 was $2.9 million, with a cash balance of $15 million at the end of Q2 2024 [12] Business Line Data and Key Metrics Changes - The company closed 17 DAAP deals in the first half of 2024, including eight in Q2, indicating strong client engagement [7] - The average revenue per top three pharma clients is $9.7 million, compared to $2.7 million for the top 20 clients, highlighting a significant disparity in revenue contribution [6][13] - The net revenue retention rate improved to 124%, up from 89% in Q2 2023 [13] Market Data and Key Metrics Changes - The company is experiencing strong demand for its DAAP solutions, with a significant number of deals in the pipeline, approximately 50% of which are from the DTC side of the business [8] - The company has seen a material separation in revenue contribution between its top clients and the broader client base, indicating a strong market position [6] Company Strategy and Development Direction - The company aims to convert over 300 supported brands to DAAP, with significant progress made since the second half of 2023 [5] - The strategy includes establishing a more consistent pricing mechanism to enhance revenue recognition and reduce volatility [5] - The company is focused on cross-selling opportunities between HCP and DTC clients, reflecting a strategic integration of services [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in revenue recognition from a delayed $6 million DAAP program expected to finalize in Q3 2024 [4][15] - The company does not anticipate a pullback in client spending for the second half of the year, despite previous timing issues [6] - Management indicated strong conviction in achieving revenue guidance for the year, with approximately $15 million remaining to meet current expectations [9][22] Other Important Information - The company continues to focus on enhancing its data analytics capabilities to provide better insights to clients, which is expected to drive future growth [25][26] - The integration of Medicx Health is progressing well, with expectations for improved performance in the second half of the year [30][31] Q&A Session Summary Question: What caused the delay in the large client deal? - Management confirmed the delay was due to internal process reviews rather than legal issues, with high conviction that the deal will commence in Q3 [14][15] Question: How is the sales pipeline trending for HCP versus DTC? - Management noted continued interest in both HCP and DTC activities, with a strong demand for integrated marketing solutions [16][18] Question: What is the current overlap with Medicx and future sales headcount needs? - Management indicated good integration with Medicx and sufficient staffing to pursue sales opportunities, with positive trends expected in the second half [19][30] Question: Can you provide insight into revenue visibility and seasonality? - Management stated they have about 80% visibility on revenue for the year, with typical seasonality showing 25-30% of revenue in Q3 [22][26] Question: What is the outlook for DAAP deal sizes and average revenue per client? - Management noted that DAAP deal sizes are increasing with client tenure, and they expect to convert more clients to similar revenue levels as top clients [27][28]

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 128.57%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.11, delivering no surprise. Over the last four quarters, the company has ...

Exhibit 99.1 OptimizeRx Reports Second Quarter 2024 Financial Results - Q2 revenue of $18.8 million, increasing 36% year-over-year - Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62% - Won 8 DAAP deals during Q2 WALTHAM, Mass. – August 8, 2024 – OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the th ...

WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call. Date: Thursday, August 8, 2024 ...

Please call the conference telephone number or log on to the web access link five minutes prior to the start time. OptimizeRx provides trailblazing technology that fosters care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the healthcare journey. With the ability to synchronize messaging across 2 million healthcare providers and over 240 million adults across a multitude of digital channels including a proprietary point-of-care ne ...

WALTHAM, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its continued commitment to partnering with pharmaceutical brands to navigate the rapidly changing landscape of state-level consumer privacy legislation while executing comprehensive marketing programs nationwide. This month Florida, Oregon, and Tex ...

WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the results of an internal marketing study demonstrating that the Company's predictive marketing technology, the Dynamic Audience Activation Platform (DAAP), can deliver superior program results for life sciences brands looking to reach and engage ...